Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

January 13, 2022

Study Completion Date

March 30, 2022

Conditions
Corona Virus Infection
Interventions
BIOLOGICAL

T memory cells and NK cells

Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).

Trial Locations (1)

28046

Hospital Universitario La Paz, Madrid

All Listed Sponsors
collaborator

Universidad Autonoma de Madrid

OTHER

collaborator

Universidad Miguel Hernandez de Elche

OTHER

collaborator

Biocruces Bizkaia Health Research Institute

OTHER_GOV

collaborator

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

OTHER

lead

Instituto de Investigación Hospital Universitario La Paz

OTHER

NCT04578210 - Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia | Biotech Hunter | Biotech Hunter